Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 2
2008 5
2009 5
2010 3
2011 3
2012 7
2013 1
2014 2
2015 1
2016 3
2017 1
2018 1
2019 2
2020 1
2021 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Use of intravenous iron and risk of anaphylaxis: A multinational observational post-authorisation safety study in Europe.
Fortuny J, von Gersdorff G, Lassalle R, Linder M, Overbeek J, Reinold J, Toft G, Timmer A, Dress J, Blin P, Droz-Perroteau C, Ehrenstein V, Franzoni C, Herings R, Kollhorst B, Moore N, Odsbu I, Perez-Gutthann S, Schink T, Rascher K, Rasouliyan L, Rothman KJ, Saigi-Morgui N, Schaller M, Smits E, Forstner M; Intravenous Iron Consortium; Bénichou J, Bircher AJ, Garbe E, Rampton DS, Gutierrez L. Fortuny J, et al. Among authors: rasouliyan l. Pharmacoepidemiol Drug Saf. 2021 Oct;30(10):1447-1457. doi: 10.1002/pds.5319. Epub 2021 Jul 12. Pharmacoepidemiol Drug Saf. 2021. PMID: 34181291 Free PMC article.
Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study.
Coates LC, Gladman DD, Nash P, FitzGerald O, Kavanaugh A, Kvien TK, Gossec L, Strand V, Rasouliyan L, Pricop L, Ding K, Jugl SM, Gaillez C; FUTURE 2 study group. Coates LC, et al. Among authors: rasouliyan l. Arthritis Res Ther. 2018 Dec 7;20(1):272. doi: 10.1186/s13075-018-1773-y. Arthritis Res Ther. 2018. PMID: 30526678 Free PMC article. Clinical Trial.
Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study.
Coates LC, Nash P, Kvien TK, Gossec L, Mease PJ, Rasouliyan L, Pricop L, Jugl SM, Gandhi KK, Gaillez C, Smolen JS. Coates LC, et al. Among authors: rasouliyan l. Semin Arthritis Rheum. 2020 Aug;50(4):709-718. doi: 10.1016/j.semarthrit.2020.03.015. Epub 2020 May 15. Semin Arthritis Rheum. 2020. PMID: 32521325 Free article. Clinical Trial.
Risk factors for rate of decline in FEV1 in adults with cystic fibrosis.
Konstan MW, Wagener JS, Vandevanter DR, Pasta DJ, Yegin A, Rasouliyan L, Morgan WJ. Konstan MW, et al. Among authors: rasouliyan l. J Cyst Fibros. 2012 Sep;11(5):405-11. doi: 10.1016/j.jcf.2012.03.009. Epub 2012 May 5. J Cyst Fibros. 2012. PMID: 22561369 Free PMC article.
Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial.
Laetsch TW, Myers GD, Baruchel A, Dietz AC, Pulsipher MA, Bittencourt H, Buechner J, De Moerloose B, Davis KL, Nemecek E, Driscoll T, Mechinaud F, Boissel N, Rives S, Bader P, Peters C, Sabnis HS, Grupp SA, Yanik GA, Hiramatsu H, Stefanski HE, Rasouliyan L, Yi L, Shah S, Zhang J, Harris AC. Laetsch TW, et al. Among authors: rasouliyan l. Lancet Oncol. 2019 Dec;20(12):1710-1718. doi: 10.1016/S1470-2045(19)30493-0. Epub 2019 Oct 9. Lancet Oncol. 2019. PMID: 31606419 Free PMC article. Clinical Trial.
32 results